Updates, Challenges, and Unmet Needs in nccRCC Treatment

By Pedro Barata, MD, Karine Tawagi, MD - Last Updated: September 16, 2024

At the ESMO Congress 2024, Dr. Pedro Barata of University Hospitals Seidman Cancer Center and Dr. Karine Tawagi of the University of Illinois provide a comprehensive update on the latest advancements in non-clear cell renal cell carcinoma (RCC). They cover:

SAMETA: A groundbreaking approach in papillary RCC
PAPMET2: New insights and implications for papillary RCC treatment
Updated NCCN Guidelines: A detailed look at the new molecular classification for RCC subtypes
SUNNIFORECAST: Emerging data and future directions for ipi/nivo in papillary, non-papillary RCC

Efficacy of Durvalumab Plus Savolitinib in MET-Driven Papillary Renal Cancer: Insights From CALYPSO

Emily MenendeznccRCC | February 19, 2025

Previous data from the phase II CALYPSO study has demonstrated the efficacy of durvalumab in combination with savolitinib.

ctDNA Monitoring Provides PFS Data for Patients With Metastatic RCC

Emily MenendeznccRCC | January 16, 2025

Serial ctDNA negativity or clearance was linked to improved PFS compared with persistent ctDNA positivity during treatment.

Survival Rates in High-Risk Non-Clear Cell RCC Comparable to Clear Cell RCC With Adjuvant Pembrolizumab Therapy

Yvette C. TerrienccRCC | December 9, 2024

New data shows patients with nccRCC may benefit from adjuvant therapy at a comparable rate as patients with ccRCC.

Adjuvant Treatments and Systemic Therapy for nccRCC

Daniel Joyce, MDnccRCC | October 19, 2024

In the final segment of this roundtable, the panelists discuss the potential of adjuvant treatments and systemic therapy.

IO/IO, IO/TKI Therapy for nccRCC and Its Effect on Next-Line Treatment

Daniel Joyce, MDnccRCC | October 19, 2024

In the fourth part of this roundtable series, the panelists discuss the use of IO/IO and IO/TKI therapy in nccRCC.

Updates, Challenges, and Unmet Needs in nccRCC Treatment

Related Posts